Captrust Financial Advisors Makes New $26,000 Investment in Assertio Holdings, Inc. (NASDAQ:ASRT)

Captrust Financial Advisors bought a new position in shares of Assertio Holdings, Inc. (NASDAQ:ASRT) during the 3rd quarter, Holdings Channel.com reports. The firm bought 22,410 shares of the company’s stock, valued at approximately $26,000.

Several other hedge funds have also recently bought and sold shares of the business. Renaissance Technologies LLC increased its position in Assertio by 13.7% during the second quarter. Renaissance Technologies LLC now owns 2,377,614 shares of the company’s stock worth $2,948,000 after buying an additional 285,655 shares during the last quarter. Empowered Funds LLC grew its position in shares of Assertio by 5.4% in the third quarter. Empowered Funds LLC now owns 431,913 shares of the company’s stock valued at $510,000 after purchasing an additional 21,976 shares during the last quarter. Perritt Capital Management Inc grew its position in shares of Assertio by 16.1% in the second quarter. Perritt Capital Management Inc now owns 426,850 shares of the company’s stock valued at $529,000 after purchasing an additional 59,333 shares during the last quarter. Palumbo Wealth Management LLC grew its position in shares of Assertio by 9.3% in the third quarter. Palumbo Wealth Management LLC now owns 185,961 shares of the company’s stock valued at $219,000 after purchasing an additional 15,863 shares during the last quarter. Finally, SummerHaven Investment Management LLC grew its position in shares of Assertio by 10.9% in the second quarter. SummerHaven Investment Management LLC now owns 161,171 shares of the company’s stock valued at $200,000 after purchasing an additional 15,779 shares during the last quarter. 48.96% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the company. HC Wainwright reaffirmed a “buy” rating and issued a $4.00 price target on shares of Assertio in a research report on Monday. StockNews.com raised Assertio from a “hold” rating to a “buy” rating in a research report on Wednesday, November 13th.

Assertio Stock Up 2.2 %

NASDAQ ASRT opened at $0.94 on Tuesday. The company has a debt-to-equity ratio of 0.30, a quick ratio of 1.57 and a current ratio of 2.01. The firm has a 50-day simple moving average of $1.01 and a 200 day simple moving average of $1.17. Assertio Holdings, Inc. has a twelve month low of $0.73 and a twelve month high of $1.80. The stock has a market cap of $89.75 million, a PE ratio of -1.29 and a beta of 0.82.

Assertio (NASDAQ:ASRT) last released its earnings results on Monday, November 11th. The company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.02. Assertio had a negative net margin of 54.46% and a positive return on equity of 3.79%. The business had revenue of $29.20 million during the quarter, compared to analysts’ expectations of $29.29 million. During the same quarter last year, the company earned ($0.01) earnings per share. On average, research analysts forecast that Assertio Holdings, Inc. will post -0.15 EPS for the current year.

Insider Activity at Assertio

In other Assertio news, Director Heather L. Mason purchased 75,000 shares of the business’s stock in a transaction on Monday, November 18th. The stock was purchased at an average price of $0.80 per share, for a total transaction of $60,000.00. Following the completion of the purchase, the director now directly owns 287,650 shares in the company, valued at approximately $230,120. This trade represents a 35.27 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 3.20% of the stock is owned by corporate insiders.

Assertio Company Profile

Assertio Holdings, Inc, a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis.